Pfizer (PFE) closed at $29.57 on Oct 16, 2026, up 0.4% on the day. The stock is up 7.0% over the past month, up 21.6% over three months, up 20.7% year to date and up 25.4% over the past year. It trades 1.0% below its 52-week high of $29.88 and 27.4% above its 52-week low of $23.21. The close sits above its 50-day moving average ($27.97) and above its 200-day moving average ($26.49).
NextPick tracks PFE in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and NVS. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month PFE ranks 3rd of 12 basket members by price change.
PFE is scheduled to report earnings on Nov 3, 2026. Over its last 8 reports the stock moved an average of 2.2% on the first trading day after earnings, beating the options-implied move in 2 of 8.
PFE options were pricing 28% at-the-money implied volatility on Oct 7, 2026, an IV rank of 58 over the past year.
Pfizer is scheduled to report on Nov 3, 2026.
Over the last 8 reports, PFE moved an average of 2.2% on the first trading day after earnings. The move beat the options-implied move in 2 of 8 reports.
Yes — the Oct 16, 2026 close of $29.57 is 11.6% above the 200-day average of $26.49.
PFE closed 1.0% below its 52-week high of $29.88.
NextPick groups PFE with JNJ, ABBV, MRK, RHHBY and NVS in its Pharma basket.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
